Literature DB >> 9059704

5-year survival and clinical prognostic factors in progressive supratentorial diffuse "low-grade" astrocytoma: a retrospective analysis of 46 cases.

P R Schuurman1, D Troost, B Verbeeten, D A Bosch.   

Abstract

In order to study survival and identify prognostic factors in progressive supratentorial low grade astrocytoma, 46 cases of diffusely growing glioma (1982-1989), in which stereotactic biopsy revealed a diagnosis of astrocytoma grade II according to Kernohan, were evaluated. Only patients with definite tumour growth on consecutive CT scans were included. All patients received a full course of fractionated radiotherapy. All tumour biopsy specimens were re-evaluated according to both the Kernohan and Daumas-Duport grading systems. Follow-up for at least 5 years showed a median survival of 47.5 months (1 year 71%, 5 year 41%). In Cox' multivariate analysis 4 factors turned out to give the best fitting prognostic model for survival: age, duration of symptoms, pre-operative neurological examination and CT-contrast enhancement. Numerical scoring was performed by giving either 1 or 0 for: age > or < 40 years, symptom duration < or > 1 year, presence or absence of focal deficit, and presence or absence of CT-contrast enhancement. Combining these factors in a score ranging from 0-4 resulted in 3 distinct groups with respect to median survival (< 2:66.5 months, 2:40 months, > 2:10 months, P = 0.0015). Although 17 cases with Kernohan grade II were upgraded using Daumas-Duport criteria (13 grade III, 4 grade IV), these cases did not form a separate survival-group. Additional parameters are needed to assess prognosis by neuropathological means, as some "low-grade" tumours are less benign than others, giving rise to a variable natural history.

Entities:  

Mesh:

Year:  1997        PMID: 9059704     DOI: 10.1007/bf01850860

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  8 in total

1.  Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.

Authors:  Barbara J Fisher; Chen Hu; David R Macdonald; Glenn J Lesser; Stephen W Coons; David G Brachman; Samuel Ryu; Maria Werner-Wasik; Jean-Paul Bahary; Junfeng Liu; Arnab Chakravarti; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-01-30       Impact factor: 7.038

2.  Prognostic significance of imaging contrast enhancement for WHO grade II gliomas.

Authors:  Johan Pallud; Laurent Capelle; Luc Taillandier; Denys Fontaine; Emmanuel Mandonnet; Rémy Guillevin; Luc Bauchet; Philippe Peruzzi; Florence Laigle-Donadey; Michèle Kujas; Jacques Guyotat; Marie-Hélène Baron; Karima Mokhtari; Hugues Duffau
Journal:  Neuro Oncol       Date:  2008-08-12       Impact factor: 12.300

3.  A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).

Authors:  Rikke H Dahlrot; Bjarne W Kristensen; Jacob Hjelmborg; Jørn Herrstedt; Steinbjørn Hansen
Journal:  J Neurooncol       Date:  2013-07-02       Impact factor: 4.130

4.  Immunohistochemical markers for prognosis of anaplastic astrocytomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

Review 5.  The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Timothy C Ryken; Ian Parney; John Buatti; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

6.  The role of MRI in patients with astrocytoma WHO II treated with fractionated stereotactic radiotherapy.

Authors:  Christian Plathow; Matthias Philipp Lichy; Peter Bachert; Ivan Zuna; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2003-11-11       Impact factor: 5.315

7.  The expression of Wnt-1 inducible signaling pathway protein-2 in astrocytoma: Correlation between pathological grade and clinical outcome.

Authors:  Gelei Xiao; Zhi Tang; Xianrui Yuan; Jian Yuan; Jie Zhao; Zhiping Zhang; Zhengwen He; Jingping Liu
Journal:  Oncol Lett       Date:  2014-11-04       Impact factor: 2.967

Review 8.  The role of imaging in the management of adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Sarah Jost Fouke; Tammie Benzinger; Daniel Gibson; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.